{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T16:43:36Z","timestamp":1782924216202,"version":"3.54.5"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004375","name":"Tel Aviv University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004375","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      The clinical significance and optimal treatment of\n                      <jats:italic>Dientamoeba fragilis<\/jats:italic>\n                      (DF) infection remain controversial, despite its frequent detection in patients with chronic gastrointestinal symptoms. This study aimed to evaluate clinical and molecular responses to various antiparasitic regimens and to assess the association between symptom resolution and parasite eradication.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this prospective, single-center observational study conducted between January 2019 and June 2023, we included 105 symptomatic patients with a positive stool PCR for DF. Patients were treated with paromomycin (PAR), nitroimidazole monotherapy (NM; metronidazole\/tinidazole), or a combination of tinidazole and albendazole (T\u2009+\u2009A). Clinical and molecular outcomes were assessed one month post-treatment using a structured symptom questionnaire and repeat PCR testing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 96 patients with follow-up, 73 underwent repeat PCR testing. PAR was associated with significantly higher clinical and molecular cure rates (82.8% and 88.5%, respectively) compared to T\u2009+\u2009A (35.0% and 29.2%) and NM (4.2% and 10.0%). Combination therapy with T\u2009+\u2009A was superior to NM in clinical response but not in molecular clearance. A strong correlation was observed between clinical cure and DF eradication (p\u2009&lt;\u20090.00001), reinforcing the pathogenic role of DF. Median symptom duration before referral was 9 months, indicating the chronic nature of untreated infection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>DF should be considered in patients with unexplained chronic gastrointestinal symptoms. Molecular testing is recommended for accurate diagnosis. Paromomycin appears to be the most effective treatment, with a strong association between clinical recovery and microbiological cure. Randomized controlled trials are warranted to further define optimal management strategies for DF infection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s15010-026-02746-6","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T08:05:14Z","timestamp":1771833914000},"page":"1319-1324","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment outcomes in symptomatic Dientamoeba fragilis infection: a prospective clinical and molecular study"],"prefix":"10.1007","volume":"54","author":[{"given":"Asaf","family":"Biber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafna","family":"Yahav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"key":"2746_CR1","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1128\/JCM.01796-10","volume":"49","author":"D Stark","year":"2011","unstructured":"Stark D, Al-Qassab SE, Barratt JLN, Stanley K, Roberts T, Marriott D, et al. Evaluation of multiplex tandem real-time PCR for detection of Cryptosporidium spp., Dientamoeba fragilis, Entamoeba histolytica, and Giardia intestinalis in clinical stool samples. J Clin Microbiol. 2011;49:257\u201362. https:\/\/doi.org\/10.1128\/JCM.01796-10.","journal-title":"J Clin Microbiol"},{"key":"2746_CR2","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1017\/S0031182000003929","volume":"10","author":"MW Jepps","year":"1918","unstructured":"Jepps MW, Dobell C. Dientamoeba fragilis n. g., n. sp., a new intestinal amoeba from man. Parasitology. 1918;10:352\u201367. https:\/\/doi.org\/10.1017\/S0031182000003929.","journal-title":"Parasitology"},{"key":"2746_CR3","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1093\/pch\/3.2.81","volume":"3","author":"J Embree","year":"1998","unstructured":"Embree J. Dientamoeba fragilis: A harmless commensal or a mild pathogen? Paediatr Child Health. 1998;3:81\u20132. https:\/\/doi.org\/10.1093\/pch\/3.2.81.","journal-title":"Paediatr Child Health."},{"key":"2746_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232315407","author":"M Jirk\u016f","year":"2022","unstructured":"Jirk\u016f M, Ka\u0161parov\u00e1 A, Lhotsk\u00e1 Z, Oborn\u00edk M, Bro\u017eov\u00e1 K, Petr\u017eelkov\u00e1 KJ, et al. A cross-sectional study on the occurrence of the intestinal protist, Dientamoeba fragilis, in the gut-healthy volunteers and their animals. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms232315407.","journal-title":"Int J Mol Sci"},{"key":"2746_CR5","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s00436-018-5771-4","volume":"117","author":"Z-W Wong","year":"2018","unstructured":"Wong Z-W, Faulder K, Robinson JL. Does Dientamoeba fragilis cause diarrhea? A systematic review. Parasitol Res. 2018;117:971\u201380. https:\/\/doi.org\/10.1007\/s00436-018-5771-4.","journal-title":"Parasitol Res"},{"key":"2746_CR6","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1128\/CMR.00076-15","volume":"29","author":"D Stark","year":"2016","unstructured":"Stark D, Barratt J, Chan D, Ellis JT. Dientamoeba fragilis, the neglected trichomonad of the human bowel. Clin Microbiol Rev. 2016;29:553\u201380. https:\/\/doi.org\/10.1128\/CMR.00076-15.","journal-title":"Clin Microbiol Rev"},{"key":"2746_CR7","unstructured":"https:\/\/www.cdc.gov\/parasites\/dientamoeba\/health_professionals\/index.html."},{"key":"2746_CR8","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1128\/AAC.05125-11","volume":"56","author":"N Nagata","year":"2012","unstructured":"Nagata N, Marriott D, Harkness J, Ellis JT, Stark D. In vitro susceptibility testing of Dientamoeba fragilis. Antimicrob Agents Chemother. 2012;56:487\u201394. https:\/\/doi.org\/10.1128\/AAC.05125-11.","journal-title":"Antimicrob Agents Chemother"},{"key":"2746_CR9","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1093\/cid\/ciu188","volume":"58","author":"D R\u00f6ser","year":"2014","unstructured":"R\u00f6ser D, Simonsen J, Stensvold CR, Olsen KEP, Bytzer P, Nielsen HV, et al. Metronidazole therapy for treating dientamoebiasis in children is not associated with better clinical outcomes: a randomized, double-blinded and placebo-controlled clinical trial. Clin Infect Dis. 2014;58:1692\u20139. https:\/\/doi.org\/10.1093\/cid\/ciu188.","journal-title":"Clin Infect Dis"},{"key":"2746_CR10","doi-asserted-by":"publisher","first-page":"e148","DOI":"10.1097\/INF.0b013e31827f4c20","volume":"32","author":"JMAT Schure","year":"2013","unstructured":"Schure JMAT, de Vries M, Weel JFL, van Roon EN, Faber TE. Symptoms and treatment of Dientamoeba fragilis infection in children, a retrospective study. Pediatr Infect Dis J. 2013;32:e148\u201350. https:\/\/doi.org\/10.1097\/INF.0b013e31827f4c20.","journal-title":"Pediatr Infect Dis J"},{"key":"2746_CR11","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s10096-024-04989-3","volume":"44","author":"HMJL Hazenberg","year":"2025","unstructured":"Hazenberg HMJL, Mank TG, Band C, Euser SM, van Soest EJ. A prospective analysis of clinical and parasitological outcomes after treatment or a wait-and-see approach of Dientamoeba fragilis infection in an adult general practice population. Eur J Clin Microbiol Infect Dis. 2025;44:143\u201350. https:\/\/doi.org\/10.1007\/s10096-024-04989-3.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2746_CR12","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ijpddr.2019.10.005","volume":"11","author":"A Burga\u00f1a","year":"2019","unstructured":"Burga\u00f1a A, Abellana R, Yordanov SZ, Kazan R, P\u00e9rez Ortiz AM, Ramos CC, et al. Paromomycin is superior to metronidazole in Dientamoeba fragilis treatment. Int J Parasitol Drugs Drug Resist. 2019;11:95\u2013100. https:\/\/doi.org\/10.1016\/j.ijpddr.2019.10.005.","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"2746_CR13","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1111\/j.1469-0691.2008.02002.x","volume":"14","author":"O Kurt","year":"2008","unstructured":"Kurt O, Girginkarde\u015fler N, Balcio\u011flu IC, Ozbilgin A, Ok UZ. A comparison of metronidazole and single-dose ornidazole for the treatment of dientamoebiasis. Clin Microbiol Infect. 2008;14:601\u20134. https:\/\/doi.org\/10.1111\/j.1469-0691.2008.02002.x.","journal-title":"Clin Microbiol Infect"},{"key":"2746_CR14","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.3201\/eid2010.140073","volume":"20","author":"E Meltzer","year":"2014","unstructured":"Meltzer E, Lachish T, Schwartz E. Treatment of giardiasis after nonresponse to nitroimidazole. Emerg Infect Dis. 2014;20:1742\u20134. https:\/\/doi.org\/10.3201\/eid2010.140073.","journal-title":"Emerg Infect Dis"},{"key":"2746_CR15","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1056\/NEJMc1101839","volume":"364","author":"R Krause","year":"2011","unstructured":"Krause R, Zollner-Schwetz I, Valentin T. Rifaximin for Irritable Bowel Syndrome without Constipation. N Engl J Med. 2011;364:1467\u20138. https:\/\/doi.org\/10.1056\/NEJMc1101839.","journal-title":"N Engl J Med."},{"key":"2746_CR16","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.eimc.2018.07.008","volume":"37","author":"C Men\u00e9ndez","year":"2019","unstructured":"Men\u00e9ndez C, Fern\u00e1ndez-Suarez J, Boga Ribeiro JA, Rodr\u00edguez-P\u00e9rez M, V\u00e1zquez F, Gonzalez-Sotorrios N, et al. Epidemiological and clinical characteristics of Dientamoeba fragilis infection. Enferm Infecc Microbiol Clin. 2019;37:290\u20135. https:\/\/doi.org\/10.1016\/j.eimc.2018.07.008.","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"2746_CR17","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00616-24","author":"A Peretz","year":"2024","unstructured":"Peretz A, Azrad M, Ken- Dror S, Strauss M, Sagas D, Parizada M, et al. The epidemiology of intestinal protozoa in the Israeli population based on molecular stool test: a nationwide study. Microbiol Spectr. 2024. https:\/\/doi.org\/10.1128\/spectrum.00616-24.","journal-title":"Microbiol Spectr"},{"key":"2746_CR18","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1017\/S0031182018001385","volume":"146","author":"RS van Gestel","year":"2019","unstructured":"van Gestel RS, Kusters JG, Monkelbaan JF. A clinical guideline on Dientamoeba fragilis infections. Parasitology. 2019;146:1131\u20139. https:\/\/doi.org\/10.1017\/S0031182018001385.","journal-title":"Parasitology"},{"key":"2746_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmni.2023.101179","volume":"54","author":"J-P Pietil\u00e4","year":"2023","unstructured":"Pietil\u00e4 J-P, H\u00e4kkinen TA, Pakarinen L, Ollgren J, Kantele A. Treatment of Dientamoeba fragilis: a retrospective Finnish analysis of faecal clearance and clinical cure comparing four antiprotozoal drugs. New Microbes New Infect. 2023;54:101179. https:\/\/doi.org\/10.1016\/j.nmni.2023.101179.","journal-title":"New Microbes New Infect"},{"key":"2746_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.parint.2020.102227","volume":"80","author":"L Clemente","year":"2021","unstructured":"Clemente L, Pasut M, Carlet R, Ruscio M, Fontana F. Dientamoeba fragilis in the North-East of Italy: prevalence study and treatment. Parasitol Int. 2021;80:102227. https:\/\/doi.org\/10.1016\/j.parint.2020.102227.","journal-title":"Parasitol Int"},{"key":"2746_CR21","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.ijpddr.2012.03.002","volume":"2","author":"JJ van Hellemond","year":"2012","unstructured":"van Hellemond JJ, Molhoek N, Koelewijn R, Wismans PJ, van Genderen PJJ. Is paromomycin the drug of choice for eradication of Dientamoeba fragilis in adults? Int J Parasitol Drugs Drug Resist. 2012;2:162\u20135. https:\/\/doi.org\/10.1016\/j.ijpddr.2012.03.002.","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"2746_CR22","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/fampra\/cmw111","volume":"34","author":"GA Holtman","year":"2017","unstructured":"Holtman GA, Kranenberg JJ, Blanker MH, Ott A, van Lisman- Leeuwen Y, Berger MY. Dientamoeba fragilis colonization is not associated with gastrointestinal symptoms in children at primary care level. Fam Pract. 2017;34:25\u20139. https:\/\/doi.org\/10.1093\/fampra\/cmw111.","journal-title":"Fam Pract"},{"key":"2746_CR23","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/taac016","author":"E Schwartz","year":"2022","unstructured":"Schwartz E, Connor BA. Persistent abdominal symptoms: a persistently neglected topic in travel medicine. J Travel Med. 2022. https:\/\/doi.org\/10.1093\/jtm\/taac016.","journal-title":"J Travel Med"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-026-02746-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-026-02746-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-026-02746-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:43:59Z","timestamp":1782920639000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-026-02746-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["2746"],"URL":"https:\/\/doi.org\/10.1007\/s15010-026-02746-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6814590\/v1","asserted-by":"object"}]},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]},"assertion":[{"value":"3 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Institutional Review Board of Sheba Medical Center. All procedures performed were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}